|
Market Cap (25-Jun) $125,067,280 (1,258th) |
Close (30-Jun) $0.007 |
Volume (30-Jun) 188,484 |
Shortsold (14-May) 14,985,846 (0.14%) (426th) |
|
52w High $0.85 |
52w Low $0.350 |
P/E 10.33 |
EPS -0.07 |
ATH released this announcement to the ASX on 31 August 2022, 18:16. The announcement is marked as price sensitive, and is 150 page(s) in length and 1.7MB in size.
You can view all announcements from ATH and see how they appear on a price chart on the announcements page.
At the date of this announcement, ATH was 0.001% short sold according to ASIC data. It was ranked the 636th most shorted stock on the ASX. It is now ranked as the 426th most shorted stock on the ASX with 0.138% of total shares short sold as of the latest reported data (14 May 2026).
| Other Recent Announcements from ATH | |
|---|---|
| Investor Presentation | 22 June 2023, 11:13 |
| ATH to present at MST Rare Diseases Rich Returns Forum | 21 June 2023, 9:52 |
| ATH starts 2nd Phase 2 Study in Rare Parkinsonian Disorder | 30 May 2023, 13:32 |
| Appendix 4E & Annual Report 2022 | 31 August 2022, 18:16 |
| Change in substantial holding | 26 August 2022, 15:13 |
| ATH434 Phase 2 clinical launched in Europe | 25 August 2022, 9:50 |
| Extension to regain NASDAQ minimum bid price compliance | 24 August 2022, 16:45 |
You must be logged in to post a reply.
Alterity Therapeutics 